Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis | 4 | 2024 | 47 | 2.150 |
Why?
|
| Neoplasms | 9 | 2024 | 3035 | 1.650 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2024 | 202 | 1.650 |
Why?
|
| Immunotherapy | 5 | 2024 | 669 | 1.550 |
Why?
|
| Autoimmune Diseases | 2 | 2023 | 249 | 1.490 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2023 | 169 | 1.490 |
Why?
|
| Rheumatology | 2 | 2021 | 35 | 1.410 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2021 | 967 | 1.410 |
Why?
|
| Steroids | 2 | 2023 | 174 | 0.980 |
Why?
|
| Sjogren's Syndrome | 2 | 2022 | 33 | 0.890 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2023 | 195 | 0.870 |
Why?
|
| Myositis | 1 | 2022 | 18 | 0.830 |
Why?
|
| Melanoma | 3 | 2023 | 467 | 0.820 |
Why?
|
| Myocarditis | 1 | 2022 | 51 | 0.800 |
Why?
|
| Osteoarthritis | 2 | 2024 | 74 | 0.800 |
Why?
|
| Myasthenia Gravis | 1 | 2022 | 83 | 0.790 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2347 | 0.750 |
Why?
|
| Teacher Training | 1 | 2019 | 2 | 0.710 |
Why?
|
| Fever | 1 | 2020 | 128 | 0.700 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 192 | 0.690 |
Why?
|
| Antirheumatic Agents | 3 | 2023 | 55 | 0.650 |
Why?
|
| Needs Assessment | 1 | 2019 | 157 | 0.640 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 260 | 0.610 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 390 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.510 |
Why?
|
| Humans | 28 | 2024 | 89063 | 0.490 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1114 | 0.480 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 643 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1363 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1043 | 0.450 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2023 | 22 | 0.440 |
Why?
|
| Interleukin-6 | 2 | 2021 | 261 | 0.340 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2023 | 1 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 833 | 0.220 |
Why?
|
| Arthritis, Psoriatic | 1 | 2023 | 34 | 0.220 |
Why?
|
| Time Factors | 2 | 2023 | 5320 | 0.210 |
Why?
|
| Medical Oncology | 2 | 2024 | 382 | 0.210 |
Why?
|
| Bias | 1 | 2023 | 131 | 0.210 |
Why?
|
| Aged | 6 | 2021 | 19077 | 0.210 |
Why?
|
| Male | 9 | 2023 | 42251 | 0.200 |
Why?
|
| Autoantibodies | 1 | 2023 | 268 | 0.200 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 17 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 699 | 0.190 |
Why?
|
| Biological Products | 1 | 2023 | 151 | 0.180 |
Why?
|
| Rituximab | 1 | 2021 | 119 | 0.180 |
Why?
|
| Retrospective Studies | 3 | 2023 | 9003 | 0.180 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 98 | 0.180 |
Why?
|
| Drug Monitoring | 1 | 2020 | 119 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 91 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 1940 | 0.170 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 144 | 0.170 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2019 | 23 | 0.170 |
Why?
|
| Facial Paralysis | 1 | 2019 | 17 | 0.170 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 108 | 0.160 |
Why?
|
| Female | 9 | 2023 | 46011 | 0.160 |
Why?
|
| Facial Nerve | 1 | 2019 | 34 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 121 | 0.160 |
Why?
|
| Middle Aged | 6 | 2023 | 25863 | 0.160 |
Why?
|
| Chicago | 1 | 2023 | 1423 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2019 | 306 | 0.160 |
Why?
|
| Rheumatic Diseases | 1 | 2018 | 26 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 345 | 0.150 |
Why?
|
| Connective Tissue Diseases | 1 | 2018 | 70 | 0.150 |
Why?
|
| Inflammation | 1 | 2022 | 971 | 0.140 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 443 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 575 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2022 | 4273 | 0.140 |
Why?
|
| Skin Diseases | 1 | 2018 | 173 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 311 | 0.120 |
Why?
|
| Curriculum | 1 | 2019 | 567 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2019 | 395 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1837 | 0.120 |
Why?
|
| Adult | 3 | 2021 | 26507 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2023 | 8203 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2612 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6777 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 783 | 0.090 |
Why?
|
| United States | 1 | 2019 | 6955 | 0.070 |
Why?
|
| Crystal Arthropathies | 1 | 2024 | 2 | 0.060 |
Why?
|
| Sarcoidosis | 1 | 2024 | 72 | 0.060 |
Why?
|
| HLA-DRB1 Chains | 1 | 2023 | 25 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2023 | 41 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2023 | 44 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 172 | 0.050 |
Why?
|
| Epitopes | 1 | 2023 | 255 | 0.050 |
Why?
|
| Methotrexate | 1 | 2023 | 250 | 0.050 |
Why?
|
| Disease Management | 1 | 2024 | 329 | 0.050 |
Why?
|
| Coinfection | 1 | 2021 | 61 | 0.050 |
Why?
|
| United Kingdom | 1 | 2021 | 164 | 0.050 |
Why?
|
| Pharmacology, Clinical | 1 | 2020 | 8 | 0.050 |
Why?
|
| Cause of Death | 1 | 2021 | 266 | 0.040 |
Why?
|
| Peptides | 1 | 2023 | 646 | 0.040 |
Why?
|
| Genes, Insect | 1 | 2000 | 183 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1591 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 72 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2000 | 169 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2000 | 289 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 357 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2019 | 61 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 352 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 273 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 127 | 0.040 |
Why?
|
| Fatigue | 1 | 2018 | 179 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 740 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1488 | 0.040 |
Why?
|
| Drosophila | 1 | 2000 | 521 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 876 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 508 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1889 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1108 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3657 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 1194 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2290 | 0.020 |
Why?
|
| Mutation | 1 | 2000 | 4132 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3443 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2000 | 97 | 0.010 |
Why?
|
| Chromosomes | 1 | 2000 | 97 | 0.010 |
Why?
|
| Larva | 1 | 2000 | 121 | 0.010 |
Why?
|
| Insect Proteins | 1 | 2000 | 89 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 313 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2000 | 121 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2000 | 392 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 418 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2000 | 229 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 1076 | 0.010 |
Why?
|
| Mitochondria | 1 | 2000 | 553 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2062 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 2327 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2000 | 661 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 3027 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 1215 | 0.010 |
Why?
|
| Animals | 1 | 2000 | 27317 | 0.000 |
Why?
|